Canaccord analyst Edward Nash downgraded Morphic (MORF) to Hold from Buy with a price target of $57, down from $66, after the company agreed to be acquired by Eli Lilly (LLY) for a purchase price of $57 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: